tbi-223
Small moleculeexperimental
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 16, 2019 (NCT03758612)
Timeline
Indications
Mechanism of action
- N-FormylmethionineINHIBITOR
N-Formylmethionine inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COC(=O)NC[C@H]1CN(c2ccc(N3CC4(COC4)C3)c(F)c2)C(=O)O1- Mol. weight
- 365.36 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5201490 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06192160 | Phase 2 | Oct 15, 2024 | National Institute of Allergy and Infectious Diseases (NIAID), TB Alliance, University of California, Berkeley, Vanderbilt University |
| NCT04865536 | Phase 1 | Feb 16, 2021 | Global Alliance for TB Drug Development |
| NCT03758612 | Phase 1 | Jan 16, 2019 | Global Alliance for TB Drug Development |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Global Alliance for TB Drug Development | Academic/Hospital | 2 | 2 | 1 | 2019 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 2024 |
| TB Alliance | Academic/Hospital | 1 | 0 | 1 | 2024 |
| University of California, Berkeley | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Vanderbilt University | Academic/Hospital | 1 | 0 | 1 | 2024 |
5 organizations
Page 1 / 1